BPC-157

BPC-157 Research Overview

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. With CAS 137525-51-0 and a molecular weight of approximately 1,419 Da, it has become one of the most widely studied research peptides in regenerative and gastroprotective science. UK laboratories, universities and contract research organisations routinely source BPC-157 for in vitro and preclinical work examining tissue repair, angiogenesis and inflammatory modulation. Peptidy supplies research-grade material at 99%+ purity with batch-specific Certificates of Analysis, supporting reproducible experimental design across multiple vial and bulk powder formats.

Mechanism of Action and Signalling Pathways

Preclinical literature suggests BPC-157 interacts with several molecular pathways relevant to wound healing and cytoprotection. Studies in rodent models report upregulation of vascular endothelial growth factor (VEGF) and enhanced nitric oxide (NO) signalling, which may promote angiogenesis at injury sites. The peptide has also been associated with modulation of the growth hormone receptor axis and interactions with the serotonergic and dopaminergic systems in gastrointestinal tissue. Unlike many anabolic agents, BPC-157 does not appear to act through classical steroid receptors; instead, researchers propose a multi-target mechanism involving extracellular matrix reorganisation, fibroblast migration and stabilisation of the gastric mucosal barrier. These findings remain confined to laboratory and animal models and do not constitute evidence for human therapeutic use.

Published Research Applications

Peer-reviewed work has explored BPC-157 in models of tendon and ligament injury, where local and systemic administration correlated with accelerated collagen organisation and improved biomechanical strength in rat Achilles tendon transection studies. Gastrointestinal research has examined its effects on NSAID-induced mucosal damage, fistula healing and inflammatory bowel models, with several papers reporting histological improvements in epithelial integrity. Neuroprotective and neuroregenerative angles — including peripheral nerve transection and spinal cord contusion models — represent an expanding area of interest. Cosmetic and dermatological researchers also evaluate BPC-157 in fibroblast proliferation assays and skin equivalent models. For UK wholesale buyers, consistent peptide sequence, endotoxin screening and stability data are critical when designing multi-month study programmes.

Analytical Characterisation and Quality Standards

High-purity BPC-157 is typically verified by reversed-phase HPLC, with identity confirmed by mass spectrometry (MS or MALDI-TOF depending on laboratory capability). Residual solvents, water content (Karl Fischer) and bacterial endotoxin levels should be documented for injectable-grade research kits. Lyophilised vials benefit from controlled moisture environments during storage; reconstitution with bacteriostatic water or sterile diluent should follow institutional SOPs. Peptidy's COA-backed batches allow traceability from synthesis through lyophilisation, giving procurement teams confidence when auditing supplier qualification files for MHRA-registered or ISO-aligned facilities.

Storage, Handling and Formulation Notes

Store lyophilised BPC-157 at −20 °C or below for long-term stability; short-term bench use at 2–8 °C is acceptable for active study windows. Reconstituted solutions should be aliquoted and frozen at −80 °C where repeated freeze-thaw cycles must be minimised. Researchers working with cell culture should confirm sterility and endotoxin thresholds before application to sensitive primary cell lines. Bulk powder at MOQ 1 g supports formulation R&D, while 10-vial kits (10 mg–80 mg per vial) suit protocol-driven dosing studies. Always label containers with batch number, reconstitution date and concentration to maintain GLP-aligned documentation.

Experimental Design Considerations for UK Laboratories

When designing BPC-157 studies, researchers should standardise administration route (intraperitoneal, subcutaneous, topical or oral gavage in animals) because pharmacokinetics differ materially between routes. Dose-ranging in rodent models typically spans low microgram per kilogram to milligram per kilogram bands reported in literature — always cross-reference primary sources rather than extrapolating from unrelated injury models. Include appropriate vehicle controls, as acetate or saline vehicles may interact with gastric protocols. For tendon research, biomechanical testing (ultimate load, stiffness) alongside histology (Masson's trichrome, Sirius red for collagen fibre alignment) strengthens dataset quality. Cell-based work should report passage number, serum batch and confluence at treatment onset, as fibroblast responsiveness varies with culture age. UK Animal Welfare Act 2006 and institutional AWERB approval govern in vivo work; Peptidy does not provide dosing guidance for animals or humans.

Combination studies pairing BPC-157 with TB-500 or GHK-Cu are increasingly common in exploratory regenerative literature. If pursuing combination protocols, procure all peptides from a single supplier batch where possible to harmonise impurity profiles and simplify bioanalytical interpretation. Document concurrent medications or growth factors in culture media that may confound angiogenesis readouts. For long-term stability of reconstituted material used in chronic dosing studies, establish internal stability-indicating data at 2–8 °C and −20 °C rather than relying solely on supplier recommendations.

Regulatory and Research Ethics Context

BPC-157 is not authorised as a medicinal product in the UK for human use. MHRA-regulated clinics and pharmacies should not compound or dispense BPC-157 for patients. University technology transfer offices and spin-outs exploring peptide therapeutics must separate research-grade procurement from GMP manufacturing pathways. Peptidy's role is limited to supplying qualified B2B buyers for lawful research. Buyers should maintain audit trails linking COA batch numbers to experimental records for publication integrity and institutional review.

Wholesale Supply from Peptidy UK

Peptidy is a UK-based B2B supplier of research peptides for qualified laboratories and institutions. We do not sell to the public for human consumption. Our BPC-157 inventory supports flexible MOQs, express UK dispatch and dedicated account management for repeat orders. For specification sheets, MSDS documentation or volume pricing on 1 g+ powder and multi-kit orders, contact our wholesale team. All products are intended strictly for in vitro and lawful preclinical research.

Further reading: BPC-157 musculoskeletal research · peptide research blog · wholesale shop